November 25, 2025

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

3 hours ago talkbio0Tagged 2025, Asymmetric Septal Hypertrophy, CAR-T, CAR-T therapy, Eli Lilly, in vivo, Kelonia Therapeutics, Multiple Myeloma, Novartis, Phase 3 trials

ASH 2025; in vivo CAR-T; Kelonia Therapeutics; KLN-1010; multiple myeloma; Johnson & Johnson; Lilly; Novartis; CAR-T therapy; Phase 3 trials

FDA Approves Novartis’ Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients

3 hours ago talkbio0Tagged Adult, Approved, gene therapy, intrathecal formulation, Itvisma, Novartis, older children, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis; FDA approval; Itvisma; Zolgensma; Spinal Muscular Atrophy (SMA); Gene Therapy; Older Children; Adults; Intrathecal Formulation

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

15 hours ago talkbio0Tagged AI-discovered drugs, ATR, ATR/mTOR Inhibitors, Brain Neoplasms, CNS-penetrant, dual pathway inhibition, Enki generative AI, preclinical data, PTEN-deficient tumors, Rakovina, Society for Neuro-Oncology

Rakovina Therapeutics; AI-discovered drugs; CNS-penetrant; ATR/mTOR inhibitors; preclinical data; Society for Neuro-Oncology; brain cancer; PTEN-deficient tumors; Enki generative AI; dual pathway inhibition